Thomas Hofmann Biography and Net Worth



Thomas W. Hofmann serves as Independent Director of the Company. Mr. Hofmann retired from Sunoco, Inc.—a diversified energy company—in 2008, where he was Senior Vice President and CFO from January 2002 to December 2008. In that role, he was responsible for managing the accounting, auditing, investor relations and strategic planning, tax and treasury functions of the organization. He also chaired the Company's Capital Management Committee and served as the management liaison to the Audit Committee. Mr. Hofmann served Sunoco in various other senior management roles since joining in 1977. Mr. Hofmann serves on the boards of Fox Chase Cancer Center and Temple University Health System. He also serves on the President's Leadership Council of the University of Delaware and is a member of the advisory board for Drexel University's Center for Corporate Governance.

What is Thomas W. Hofmann's net worth?

The estimated net worth of Thomas W. Hofmann is at least $15.72 million as of May 1st, 2023. Mr. Hofmann owns 43,616 shares of West Pharmaceutical Services stock worth more than $15,720,515 as of April 28th. This net worth evaluation does not reflect any other investments that Mr. Hofmann may own. Learn More about Thomas W. Hofmann's net worth.

How do I contact Thomas W. Hofmann?

The corporate mailing address for Mr. Hofmann and other West Pharmaceutical Services executives is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. West Pharmaceutical Services can also be reached via phone at (610) 594-2900 and via email at [email protected]. Learn More on Thomas W. Hofmann's contact information.

Has Thomas W. Hofmann been buying or selling shares of West Pharmaceutical Services?

Thomas W. Hofmann has not been actively trading shares of West Pharmaceutical Services within the last three months. Most recently, Thomas W. Hofmann sold 1,212 shares of the business's stock in a transaction on Monday, May 1st. The shares were sold at an average price of $365.57, for a transaction totalling $443,070.84. Following the completion of the sale, the director now directly owns 43,616 shares of the company's stock, valued at $15,944,701.12. Learn More on Thomas W. Hofmann's trading history.

Who are West Pharmaceutical Services' active insiders?

West Pharmaceutical Services' insider roster includes Silji Abraham (Insider), Bernard Birkett (SVP), Annette Favorite (VP), Eric Green (CEO), Thomas Hofmann (Director), Quintin Lai (VP), George Miller (VP), Cindy Reiss-Clark (Insider), Chad Winters (CAO), and Patrick Zenner (Director). Learn More on West Pharmaceutical Services' active insiders.

Are insiders buying or selling shares of West Pharmaceutical Services?

In the last twelve months, insiders at the medical instruments supplier sold shares 17 times. They sold a total of 202,177 shares worth more than $74,559,298.70. The most recent insider tranaction occured on March, 11th when CAO Chad Winters sold 815 shares worth more than $292,438.30. Insiders at West Pharmaceutical Services own 0.5% of the company. Learn More about insider trades at West Pharmaceutical Services.

Information on this page was last updated on 3/11/2024.

Thomas W. Hofmann Insider Trading History at West Pharmaceutical Services

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2023Sell1,212$365.57$443,070.8443,616View SEC Filing Icon  
5/25/2016Sell2,466$73.57$181,423.6234,506View SEC Filing Icon  
2/29/2016Sell3,042$62.70$190,733.4034,637View SEC Filing Icon  
See Full Table

Thomas W. Hofmann Buying and Selling Activity at West Pharmaceutical Services

This chart shows Thomas W Hofmann's buying and selling at West Pharmaceutical Services by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

West Pharmaceutical Services Company Overview

West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $360.43
Low: $358.89
High: $370.00

50 Day Range

MA: $377.63
Low: $350.18
High: $399.39

2 Week Range

Now: $360.43
Low: $310.42
High: $415.73

Volume

603,058 shs

Average Volume

378,628 shs

Market Capitalization

$26.39 billion

P/E Ratio

47.55

Dividend Yield

0.22%

Beta

1.04